Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rauwolfia vomitoria extract is a botanical preparation derived from the root, bark, or leaf of the Rauwolfia vomitoria plant, which is native to West Africa and used in both traditional and experimental medicine settings. The extract contains several phytochemicals, including alkaloids (such as reserpine, reserpinine, deserpidine, ajmalicine, and ajmaline), saponins, flavonoids, cardiac glycosides, phytosterols, vitamin E, lupeol, and vaccenic acid[2][3][7]. It possesses diverse pharmacological activities, including antihypertensive (blood pressure lowering), antiproliferative (notably for benign prostatic hyperplasia), antimicrobial, anti-inflammatory, immunomodulatory, antioxidant, and antitumor/cancer potential[1][2][5][8][10]. Mechanistically, it is reported to suppress androgen receptor signaling and related pathways in models of benign prostatic hyperplasia, reduce proliferation markers, and decrease steroid 5α-reductase 1 expression[1]. The extract also demonstrates significant antioxidant properties, likely due to its phenolic content[8]. Rauwolfia vomitoria extract is distinguishable from single-compound drugs like reserpine, as it contains a complex mixture of bioactive constituents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rauwolfia vomitoria extract.